American Academy of Dermatology Annual Meeting: Orlando, FL, USA, 7-11 March 2025

被引：0
作者：
Fraser, Kathy A. [1 ]
机构：
[1] Adis Int Ltd, Springer Nat, 74 Taharoto Rd, Auckland 0622, New Zealand
来源：
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY | 2025年 / 26卷 / 03期
关键词：
MODERATE; EFFICACY;
D O I：
10.1007/s40257-025-00945-9
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：471 / 474
页数：4
相关论文
共 18 条
[1]   An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis [J].
Bissonnette, Robert ;
Pinter, Andreas ;
Ferris, Laura K. ;
Gerdes, Sascha ;
Rich, Phoebe ;
Vender, Ronald ;
Miller, Megan ;
Shen, Yaung-Kaung ;
Kannan, Arun ;
Li, Shu ;
Deklotz, Cynthia ;
Papp, Kim .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (06) :510-521
[2]  
Blauvelt A, 2025, AM ACAD DERMATOLOGY
[3]  
Croft M, 2024, AM J CLIN DERMATOL, V25, P447, DOI 10.1007/s40257-023-00838-9
[4]   FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis [J].
Ferris, Laura K. ;
Bagel, Jerry ;
Huang, Yu-Huei ;
Pink, Andrew E. ;
Tyring, Stephen K. ;
Kokolakis, Georgios ;
Delozier, Amy M. ;
Li, Shu ;
Shen, Yaung-Kaung ;
Iaconangelo, Charles ;
Ota, Takayuki ;
Bissonnette, Robert .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (03) :495-502
[5]  
Guttman-Yassky E, 2025, AM ACAD DERMATOLOGY
[6]   An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study [J].
Guttman-Yassky, Emma ;
Simpson, Eric L. ;
Reich, Kristian ;
Kabashima, Kenji ;
Igawa, Ken ;
Suzuki, Tetsuya ;
Mano, Hirotaka ;
Matsui, Takeshi ;
Esfandiari, Ehsanollah ;
Furue, Masutaka .
LANCET, 2023, 401 (10372) :204-214
[7]   Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis [J].
Hoy, Sheridan M. .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (01) :143-151
[8]  
Icotrokinra a targeted oral peptide that selectively blocks the interleukin-23 receptor for the treatment of moderate-to-severe plaque psoriasis: Results through week 24 of the phase 3 randomized double-blind placebo-controlled ICONIC-LEAD trial. Late-breaking abstract. American Academy of Dermatology Annual Meeting 711, 2025, ORLANDO
[9]   Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo [J].
Kang, Connie .
DRUGS, 2024, :579-586
[10]   Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update [J].
Karakioulaki, Meropi ;
Eyerich, Kilian ;
Patsatsi, Aikaterini .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (02) :195-212
12